SCHEMBL11030051

SCHEMBL11030051

CN1CCN(c2ccc(Nc3cc(-c4cccnc4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.57
▸ DYRK1A Q13627 2/20 0.50
▸ IRAK4 Q9NWZ3 1/20 0.50
▸ MAPKAPK2 P49137 4/20 0.49
▸ AURKA O14965 3/20 0.48
▸ CDK4 P11802 2/20 0.48
▸ CDK2 P24941 2/20 0.48
▸ CCNA2 P20248 1/20 0.48
▸ CCND3 P30281 1/20 0.48
▸ CDK6 Q00534 1/20 0.48
▸ MAP4K1 Q92918 1/20 0.47
▸ FYN P06241 1/20 0.47
▸ PIM1 P11309 1/20 0.47
▸ TTK P33981 1/20 0.47
▸ PIM2 Q9P1W9 1/20 0.47
▸ SYK P43405 1/20 0.46
▸ STAT6 P42226 1/20 0.46
▸ CLK1 P49759 1/20 0.46
▸ EGFR P00533 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029599 0.90 MAPKAPK2 (0.58) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11029346 0.87 MAPKAPK2 (0.61) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11026741 0.87 FYN (0.55) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11031445 0.87 SLC2A1 (0.51) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11027433 0.86 MAPKAPK2 (0.60) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11030064 0.86 CHEK1 (0.56) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11031767 0.84 SLC2A1 (0.50) SLC2A1DYRK1AMAPKAPK2AURKACDK4
SCHEMBL11029146 0.84 SLC2A1 (0.49) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11028611 0.83 SLC2A1 (0.51) SLC2A1MAPKAPK2AURKACDK4CDK2
SCHEMBL11031045 0.83 RAD52 (0.55) SLC2A1MAPKAPK2AURKACDK4CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885DYRK1A 501/4885IRAK4 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback